VWR International, LLC to Distribute Illumina’s qPCR Portfolio

  VWR International, LLC to Distribute Illumina’s qPCR Portfolio

             Dramatically Expands Sales Reach Within U.S. Market

Business Wire

SAN DIEGO -- November 12, 2012

Illumina, Inc. (NASDAQ:ILMN) today announced that VWR International, LLC, a
global distributor of laboratory supplies and services, will distribute
Illumina’s qPCR portfolio including the Eco™ Real-Time PCR System and NuPCR™
reagents within the United States, one of the world’s largest qPCR
instrumentation markets. The agreement extends Illumina’s reach for its
innovative Eco System and novel NuPCR probe-based technology into thousands of
laboratories and facilities nationwide, by leveraging VWR’s 150 years of
industry experience and its well-established distribution network.

“Complementing Illumina’s commercialization efforts with VWR’s talented team
of sales and services representatives enables us to significantly expand
promotion and support of both the Eco System and NuPCR reagents in molecular
biology laboratories throughout the United States,” said Mark Lewis, Senior
Vice President and General Manager of Illumina’s Molecular Biology and PCR
Business. “We are very excited to join forces with VWR to accelerate adoption
of our qPCR portfolio, particularly into the pharmaceutical and industrial
markets where VWR has a strong presence.”

Real time PCR is a precise, highly sensitive PCR method with applications in
basic research and diagnostics, where, for example, it is used for
quantitation of gene expression targets, verification of array data, and
pathogen detection. Illumina’s Eco Real-Time PCR System is an affordable,
compact instrument that allows researchers to perform any qPCR application
directly on their bench top and is an economical alternative to traditional
large, expensive PCR instruments. The company’s novel, NuPCR probe-based qPCR
technology is designed to show improved specificity and sensitivity to complex
gene targets, as compared to existing qPCR technologies on the market today.
It is compatible with any real-time PCR instrument platform, offering
researchers a wider range of reagent choices to implement on their existing
instrumentation.

“Illumina’s qPCR portfolio adds tremendous value to our existing PCR solutions
portfolio,” said Bill Molnar, Vice President of Category Management, Life
Sciences, VWR. “Both of our companies are committed to enabling the world’s
scientists to accelerate research. The addition of the Eco System and NuPCR
reagents provides an essential element to our product line, empowering us to
effectively support key customer segments.”

Customer orders for Illumina’s qPCR portfolio through VWR will be accepted
starting December 1, 2012.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com